| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Fabrizio Turiaco, Chiara Cullotta, Federica Mannino, Antonio Bruno, Francesco Squadrito, Giovanni Pallio, Natasha Irrer. Attention Deficit Hyperactivity Disorder (ADHD) and Polyphenols: A Systematic Review. International journal of molecular sciences. vol 25. issue 3. 2024-02-10. PMID:38338814. |
thus, a neuroinflammatory state may influence the neurotransmitters pathways, such as the noradrenergic, glutamatergic, serotoninergic, and, in particular, dopaminergic ones, whose impairment is strongly associated with attention deficit hyperactivity disorder (adhd). |
2024-02-10 |
2024-02-12 |
Not clear |
| Takashi Suto, Daiki Kato, Ikuya Koibuchi, Yuki Arai, Jo Ohta, Tadanao Hiroki, Hideaki Obata, Shigeru Sait. Rat model of attention-deficit hyperactivity disorder exhibits delayed recovery from acute incisional pain due to impaired descending noradrenergic inhibition. Scientific reports. vol 13. issue 1. 2023-04-04. PMID:37016045. |
attenuated noradrenergic endogenous analgesia can produce acute pain chronification, and dysfunction of noradrenergic systems in the nervous system is relevant to adhd symptoms. |
2023-04-04 |
2023-08-14 |
rat |
| Takashi Suto, Daiki Kato, Ikuya Koibuchi, Yuki Arai, Jo Ohta, Tadanao Hiroki, Hideaki Obata, Shigeru Sait. Rat model of attention-deficit hyperactivity disorder exhibits delayed recovery from acute incisional pain due to impaired descending noradrenergic inhibition. Scientific reports. vol 13. issue 1. 2023-04-04. PMID:37016045. |
noxious stimuli-induced analgesia (nsia) is measured to estimate noradrenergic endogenous analgesia in spontaneously hypertensive rats (shr) as an adhd model and control. |
2023-04-04 |
2023-08-14 |
rat |
| Takashi Suto, Daiki Kato, Ikuya Koibuchi, Yuki Arai, Jo Ohta, Tadanao Hiroki, Hideaki Obata, Shigeru Sait. Rat model of attention-deficit hyperactivity disorder exhibits delayed recovery from acute incisional pain due to impaired descending noradrenergic inhibition. Scientific reports. vol 13. issue 1. 2023-04-04. PMID:37016045. |
these results suggest adhd patients exhibit acute pain chronification due to pre-existing attenuated noradrenergic endogenous analgesia. |
2023-04-04 |
2023-08-14 |
rat |
| Maria Ptukha, Zoia Fesenko, Anastasia Belskaya, Arina Gromova, Arseniy Pelevin, Natalia Kurzina, Raul R Gainetdinov, Anna Volnov. Effects of Atomoxetine on Motor and Cognitive Behaviors and Brain Electrophysiological Activity of Dopamine Transporter Knockout Rats. Biomolecules. vol 12. issue 10. 2022-10-27. PMID:36291693. |
changes in dopaminergic and noradrenergic transmission are considered to be the underlying cause of attention deficit and hyperactivity disorder (adhd). |
2022-10-27 |
2023-08-14 |
rat |
| Takanobu Yamamot. The relationship between central fatigue and Attention Deficit/Hyperactivity Disorder of the inattentive type. Neurochemical research. 2022-08-11. PMID:35951201. |
notably, noradrenergic neuronal dysfunction is associated with the characteristic inattention of adhd. |
2022-08-11 |
2023-08-14 |
Not clear |
| Tayebeh Noori, Mousa Sahebgharani, Antoni Sureda, Eduardo Sobarzo-Sanchez, Sajad Fakhri, Samira Shirooi. Targeting PI3K by Natural Products: A potential therapeutic strategy for Attention-Deficit Hyperactivity Disorder? Current neuropharmacology. 2022-01-19. PMID:35043762. |
adhd may be associated with deficits in inhibitory frontostriatal noradrenergic neurons on lower striatal structures that are predominantly driven by dopaminergic neurons. |
2022-01-19 |
2023-08-13 |
human |
| Tayebeh Noori, Mousa Sahebgharani, Antoni Sureda, Eduardo Sobarzo-Sanchez, Sajad Fakhri, Samira Shirooi. Targeting PI3K by Natural Products: A potential therapeutic strategy for Attention-Deficit Hyperactivity Disorder? Current neuropharmacology. 2022-01-19. PMID:35043762. |
since pi3ks play an important role in the control of the noradrenergic neuron, it opens up new insights in research on adhd and other developmental brain diseases. |
2022-01-19 |
2023-08-13 |
human |
| John Michael Holde. Effects of two kinds of noradrenergic ADHD medicines on sign-tracking and goal-tracking in male rats. Experimental and clinical psychopharmacology. 2021-12-30. PMID:34968108. |
effects of two kinds of noradrenergic adhd medicines on sign-tracking and goal-tracking in male rats. |
2021-12-30 |
2023-08-13 |
rat |
| John Michael Holde. Effects of two kinds of noradrenergic ADHD medicines on sign-tracking and goal-tracking in male rats. Experimental and clinical psychopharmacology. 2021-12-30. PMID:34968108. |
in this work, i examined the role of norepinephrine by employing two noradrenergic drugs used for attention-deficit hyperactivity disorder (adhd)-(a) atomoxetine, a norepinephrine reuptake blocker, and (b) guanfacine, an α |
2021-12-30 |
2023-08-13 |
rat |
| Danfeng Yuan, Manxue Zhang, Yan Huang, Xinwei Wang, Jian Jiao, Yi Huan. Noradrenergic genes polymorphisms and response to methylphenidate in children with ADHD: A systematic review and meta-analysis. Medicine. vol 100. issue 46. 2021-11-22. PMID:34797323. |
noradrenergic genes polymorphisms and response to methylphenidate in children with adhd: a systematic review and meta-analysis. |
2021-11-22 |
2023-08-13 |
Not clear |
| Danfeng Yuan, Manxue Zhang, Yan Huang, Xinwei Wang, Jian Jiao, Yi Huan. Noradrenergic genes polymorphisms and response to methylphenidate in children with ADHD: A systematic review and meta-analysis. Medicine. vol 100. issue 46. 2021-11-22. PMID:34797323. |
this meta-analysis was conducted to evaluate whether noradrenergic gene polymorphisms impact the efficacy of mph in children with adhd. |
2021-11-22 |
2023-08-13 |
Not clear |
| Marco Pozzi, Silvana Bertella, Erika Gatti, Gabriëlla G A M Peeters, Carla Carnovale, Stefania Zambrano, Maria Nobil. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). Expert opinion on emerging drugs. vol 25. issue 4. 2021-03-16. PMID:32938246. |
current pharmacological treatments for adhd are based on stimulant or non-stimulant medications, targeting dopaminergic and noradrenergic systems in the frontal cortex and dopaminergic system in the basal ganglia. |
2021-03-16 |
2023-08-13 |
Not clear |
| Andrew J Cutler, Gregory W Mattingly, Rakesh Jain, Welton O'Nea. Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS spectrums. 2021-01-25. PMID:33121553. |
with more than 30 classical schedule ii (cii) stimulant preparations available for adhd treatment, only three nonstimulants (atomoxetine and extended-release formulations of clonidine and guanfacine) have been approved by the united states food and drug administration (fda), all of which focus on modulating the noradrenergic system. |
2021-01-25 |
2023-08-13 |
Not clear |
| Andrew J Cutler, Gregory W Mattingly, Rakesh Jain, Welton O'Nea. Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS spectrums. 2021-01-25. PMID:33121553. |
given the heterogeneity and complex nature of adhd in most patients, research efforts are identifying nonstimulants which modulate pathways beyond the noradrenergic system. |
2021-01-25 |
2023-08-13 |
Not clear |
| Jae-Won Choi, A-Hyun Jung, Sojeong Nam, Kyoung Min Kim, Jun Won Kim, Soo Yeon Kim, Bung-Nyun Kim, Jae-Won Ki. Interaction between lead and noradrenergic genotypes affects neurocognitive functions in attention-deficit/hyperactivity disorder: a case control study. BMC psychiatry. vol 20. issue 1. 2020-12-29. PMID:32791971. |
we aimed to evaluate neurocognitive functions associated with lead in the blood and the interactions between lead and dopaminergic or noradrenergic pathway-related genotypes in youths with adhd. |
2020-12-29 |
2023-08-13 |
Not clear |
| Jens Teichert, James B Rowe, Karen D Ersche, Nikolina Skandali, Julia Sacher, Achim Aigner, Ralf Regentha. Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies
. International journal of clinical pharmacology and therapeutics. vol 58. issue 8. 2020-11-09. PMID:32449675. |
atomoxetine and escitalopram are potent and selective drugs approved for noradrenergic or serotonergic modulation of neuronal networks in attention-deficit hyperactivity disorder (adhd) or depression, respectively. |
2020-11-09 |
2023-08-13 |
human |
| Kanit Tha Deang, Hatta Sidi, Hazli Zakaria, Raja Lope Adam, Srijit Das, Nurul Hazwani Hatta, Muhammad Hizri Hatta, Kok Wei We. The Novelty of Bupropion As a Dopaminergic Antidepressant for the Treatment of Adult Attention Deficit Hyperactive Disorder. Current drug targets. vol 20. issue 2. 2020-03-31. PMID:28494748. |
bupropion, an ndri has a novel effect on adhd as the molecule exerts its effects by modulating the reward-pleasure mesolimbic dopaminergic system and at the same time regulates the elevating mood dimension of the noradrenergic neurotransmission. |
2020-03-31 |
2023-08-13 |
Not clear |
| N Sekaninova, M Mestanik, A Mestanikova, A Hamrakova, I Tonhajzerov. Novel approach to evaluate central autonomic regulation in attention deficit/hyperactivity disorder (ADHD). Physiological research. vol 68. issue 4. 2020-02-10. PMID:31177787. |
according to current knowledge, adhd is defined as a biological dysfunction of central nervous system with genetically or organically defined deficits in noradrenergic and dopaminergic neurotransmission associated with structural abnormalities, especially in prefronto-striatal regions. |
2020-02-10 |
2023-08-13 |
Not clear |
| B. Spivak, Y. Vered, R. Yoran-Hegesh, E. Graff, E. Averbuch, S. Vinokurow, A. Weizman, R. Meste. The influence of three months of methylphenidate treatment on platelet-poor plasma biogenic amine levels in boys with attention deficit hyperactivity disorder. Human psychopharmacology. vol 16. issue 4. 2019-11-20. PMID:12404569. |
this result indicates the possible role of overactivity of the noradrenergic system in the pathophysiology of adhd and suggests that the mph therapeutic action may be related to stimulant-induced inhibitory effect on the noradrenergic system. |
2019-11-20 |
2023-08-12 |
Not clear |